Frederic De Ceuninck

Neurology And Immuno Inflammation Therapeutic Area, Servier R&D Center
Gif-sur-yvette, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease.

Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease.

Journal: Trends in pharmacological sciences
Published: August 01, 2024

Targeting galectin-3 in inflammatory and fibrotic diseases.

Targeting galectin-3 in inflammatory and fibrotic diseases.

Journal: Trends in pharmacological sciences
Published: April 15, 2023

Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis.

Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis.

Journal: Nature communications
Published: October 28, 2022

Design, synthesis and biological evaluation of conformationnally-restricted analogues of E7010 as inhibitors of tubulin assembly (ITA) and vascular disrupting agents (VDA).

Design, synthesis and biological evaluation of conformationnally-restricted analogues of E7010 as inhibitors of tubulin assembly (ITA) and vascular disrupting agents (VDA).

Journal: European journal of medicinal chemistry
Published: July 21, 2022

Gremlin-1 and BMP-4 Overexpressed in Osteoarthritis Drive an Osteochondral-Remodeling Program in Osteoblasts and Hypertrophic Chondrocytes.

Gremlin-1 and BMP-4 Overexpressed in Osteoarthritis Drive an Osteochondral-Remodeling Program in Osteoblasts and Hypertrophic Chondrocytes.

Journal: International journal of molecular sciences
Published: January 14, 2022

Applications of transcriptomics in support of drug development for osteoarthritis.

Applications of transcriptomics in support of drug development for osteoarthritis.

Journal: Osteoarthritis and cartilage open
Published: May 17, 2021

Pharmacological characterization of GLPG1972/S201086, a potent and selective small-molecule inhibitor of ADAMTS5.

Pharmacological characterization of GLPG1972/S201086, a potent and selective small-molecule inhibitor of ADAMTS5.

Journal: Osteoarthritis and cartilage
Published: March 15, 2021

Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis.

Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis.

Journal: Journal of medicinal chemistry
Published: March 15, 2021

IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases.

IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases.

Journal: Drug discovery today
Published: February 24, 2021

S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases.

S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases.

Journal: Journal of translational autoimmunity
Published: November 24, 2020

Neuromedin B promotes chondrocyte differentiation of mesenchymal stromal cells via calcineurin and calcium signaling.

Neuromedin B promotes chondrocyte differentiation of mesenchymal stromal cells via calcineurin and calcium signaling.

Journal: Cell & bioscience
Published: October 28, 2020

Establishment of a collection of human pluripotent stem cell lines (iPSC) from mesenchymal stem cells (MSC) from three healthy elderly donors.

Establishment of a collection of human pluripotent stem cell lines (iPSC) from mesenchymal stem cells (MSC) from three healthy elderly donors.

Journal: Stem cell research
Published: October 17, 2020
Showing 1-12 of 29

Last Updated: 09/26/2026